Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.
Yasuyoshi MiyataYuichiro NakamuraTakuji YasudaTomohiro MatsuoKojiro OhbaBungo FurusatoJunya FukuokaHideki SakaiPublished in: The Prostate (2017)
NHT stimulated cancer cell progression and BCR via up-regulation of lymphangiogenesis-related parameters in patients with low-risk PCa. Although VEGF-C and VEGF-D expressions were not changed by NHT, lymph vessel density and area were increased in low-risk PCa patients. We suggest that NHT for patients with low-risk PCa may have a high risk for BCR after RP.
Keyphrases
- radical prostatectomy
- prostate cancer
- acute lymphoblastic leukemia
- end stage renal disease
- vascular endothelial growth factor
- endothelial cells
- newly diagnosed
- chronic kidney disease
- tyrosine kinase
- ejection fraction
- chronic myeloid leukemia
- rectal cancer
- type diabetes
- squamous cell carcinoma
- polycystic ovary syndrome
- metabolic syndrome
- locally advanced
- insulin resistance